Corneal Thinning During Topical Bevacizumab Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by Yonsei University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
NCT00515684
First received: August 13, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted
  Purpose

The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.


Condition Intervention
Corneal Neovascularization
Drug: bevacizumab (Avastin)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Resource links provided by NLM:


Further study details as provided by Yonsei University:

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • clinical diagnosis of corneal neovascularization
  • must be able to apply eyedrop

Exclusion Criteria:

  • have active keratitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00515684

Contacts
Contact: Tae Im Kim, M.D. 82-2-2228-3592 tikim@yumc.yonsei.ac.kr

Locations
Korea, Republic of
Severance hospital Recruiting
Seoul, Korea, Republic of
Contact: Tae Im Kim, M.D.    82-2-2228-3592    tikim@yumc.yonsei.ac.kr   
Sponsors and Collaborators
Yonsei University
Investigators
Principal Investigator: Sang Woo Kim, M.D. Severance hospital, Seoul , Korea
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00515684     History of Changes
Other Study ID Numbers: 4-2006-0234
Study First Received: August 13, 2007
Last Updated: August 13, 2007
Health Authority: Korea: Institutional Review Board

Additional relevant MeSH terms:
Neovascularization, Pathologic
Corneal Neovascularization
Metaplasia
Pathologic Processes
Corneal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 23, 2014